帕利哌酮缓释片与喹硫平在精神分裂症急性期的疗效的对照研究

摘要

目的：比较帕利哌酮缓释片与喹硫平在治疗精神分裂症急性期中的疗效及耐受性。方法将符合入组的62例患者随机分入帕利哌酮组（3～12 mg/d，n＝30）和喹硫平组（300～750 mg/d，n＝32），进行为期4周的观察治疗，分别在治疗的0、1、2、4周进行量表评估，使用PANSS、BPRS、CGI-S对药物疗效进行评估，使用TESS、SAS量表对药物的耐受性进行评估。其中有2例使用帕利哌酮的患者因经济原因退出研究，1例使用喹硫平的患者因为明显增强的冲动行为换用其他药物治疗，共59例患者完成了最终的试验。结果两组患者在治疗4周后PANSS量表减分率、BPRS分值差以及CGI-S较基线均有明显改善（P＜0．001），两组间比较在治疗的第1周末PANSS评分结果具有统计学意义，帕利哌酮组的起效时间快，优于奎硫平组（P＜0．05）。两组均未出现严重的药物不良反应，TESS以及SAS评分没有统计学意义（P＞0．05）。结论帕利哌酮和喹硫平在精神分裂症的急性期治疗上效果好，而帕利哌酮起效速度优于喹硫平，两药物均有良好的耐受性。%Objective To evaluate the efficacy and tolerability of paliperidone ( ER) and quetiapine in patients with acute schizophrenia .Methods 62 patients were randomized to paliperidone ( ER) group(3~12mg/d n=30) and quetiapine group(300~750mg/d n=32), treating for 4 weeks, during the treating, we assessed efficacy and tolerability in 0,1,2 and 4weeks by PANSS, BPRS, CGI-S, TESS and SAS.Results After 4 weeks treatment , patients in two groups were all fairly improved in CGI-S, extremely dropped in PANSS and BPRS ( P<0.01), and there's significantly different between two groups (P<0.05),paliperidone(ER) was quickly then quetiapine in the first week's treatment .The total scores of TESS and SAS had no significantly different between two groups(P>0.05).Conclusions Paliperidone(ER) was more efficacy and faster then quetiapine on treating acute schizophrenia , two drugs were generllay well tolerated .